- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00672594
Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy
31 juillet 2014 mis à jour par: Duke University
Investigator-Initiated Pilot Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy
The purpose of this study is to look at blood and tissue samples for changes following the use of Sunitinib malate.
Additionally, we would like to find out if the drug, Sunitinib malate, is safe and works in men with prostate cancer.
Sunitinib malate , also known as Sutent, is approved by the U.S. Food and Drug Administration (FDA), for treatment of tumors of intestines and kidney but it is being tested in research studies for use in men with prostate cancer.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Description détaillée
Eligible patients will be treated with 50 mg once daily for four weeks followed by one to two weeks off treatment prior to undergoing radical prostatectomy.
Patients with palpable disease (cT2-3) and patients with 3 or more positive prostatic biopsies from one lobe may undergo an additional study of IFP monitoring before treatment and during week 4 of study treatment.
Safety and tolerability of Sunitinib malate therapy at this dose and schedule in this patient population will be assessed.
Extensive correlative science evaluations, including assessment of physiologic, cellular, molecular and genetic changes during treatment with Sunitinib malate, will be performed
Type d'étude
Interventionnel
Inscription (Réel)
30
Phase
- Phase 2
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
North Carolina
-
Durham, North Carolina, États-Unis, 27710
- Duke University Medical Center
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- MD Anderson, University of Texas
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans et plus (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Homme
La description
Inclusion Criteria:
- Histologic evidence of adenocarcinoma of the prostate deemed candidates for curative RRP
- Intermediate or high risk, clinically localized disease
- Adequate organ function
- Patients must be surgically sterile or must agree to use effective contraception during the period of therapy
- Select imaging to rule out metastasis will be done as clinically indicated
- Signed and date informed consent document
Exclusion Criteria:
- Prior treatment for prostate cancer
- Major surgery or radiation therapy within 4 weeks of starting the study treatment
- NCI CTCAE grade 3 hemorrhage within 4 weeks of starting therapy
- History of or known metastatic prostate cancer
- Any of the following within the 6 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism.
- Ongoing cardiac dysrhythmias of NCI CTCAE grade 2 or greater
- QTc interval > 500 msec on baseline EKG
- Hypertension that cannot be controlled by medications (>150/100 mm Hg despite optimal medical therapy).
- Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication
- Known active infection
- Concurrent treatment on another clinical trial. Supportive care trials or non-treatment trials, e.g. QOL, are allowed.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the subject inappropriate for entry into this study.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Sunitinib Malate
Sunitinib Malate 50mg capsule by mouth once daily for 4 weeks
|
Sunitinib Malate 50mg capsule by mouth once daily for 4 weeks
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Change in Apoptotic Indices Before and After Treatment
Délai: Baseline and 4 weeks
|
Pathologic changes will be described using immuno-histochemical techniques (assessment of apoptotic/proliferative indices and microvessel density (MVD)) using paraffin-embedded samples and freshly cut slides from the block which are deparaffinized and rehydrated through graded alcohol, where applicable.
Antigen retrieval will be accomplished by microwaving in citrate buffer from 5 to 7 minutes for the Ki-67 and MVD analysis.
Mean difference in %apoptosis (measured as %TUNEL positive cells per high powered field) between pre and post treatment will be reported.
|
Baseline and 4 weeks
|
Change in Proliferation Indices Before and After Treatment
Délai: Baseline and 4 weeks
|
Pathologic changes will be described using immuno-histochemical techniques (assessment of apoptotic/proliferative indices and microvessel density (MVD)) using paraffin-embedded samples and freshly cut slides from the block which are deparaffinized and rehydrated through graded alcohol, where applicable.
Antigen retrieval will be accomplished by microwaving in citrate buffer from 5 to 7 minutes for the Ki-67 and MVD analysis.
Mean difference in %proliferation (Ki67 positive nuclei out of total nuclei) between pre and post treatment will be reported.
|
Baseline and 4 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Number of Patients Experiencing Grade ≥4 Hematologic or Grade ≥3 Non-hematologic Toxicity
Délai: 4 years
|
Adverse events were collected using Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 and were converted to version 4.0 for the purposes of ClinicalTrials.gov
reporting.
|
4 years
|
Change in Pathologic (Microvessel Density).
Délai: Baseline and 4 weeks
|
Pathologic changes will be described using immuno-histochemical techniques (assessment of microvessel density (MVD)) using paraffin-embedded samples and freshly cut slides from the block which are deparaffinized and rehydrated through graded alcohol, where applicable.
Antigen retrieval will be accomplished by microwaving in citrate buffer from 5 to 7 minutes for the MVD analysis.
Results are reported as the difference in pre and post MVD.
Units for MVD are number of CD31 cells per high powered field.
|
Baseline and 4 weeks
|
Change in Systemic Parameters Before and After Sunitinib Malate Treatment.
Délai: Baseline and 4 weeks
|
We evaluated candidate biomarkers of this pathway to predict for pharmacodynamic response to Sunitinib malate.
In addition, a 7 ml plasma sample was collected at baseline and again at 4 weeks on all patients to assess possible biomarkers of response.
Reported is the mean percent change in plasma concentration for each marker between 4 weeks and baseline.
|
Baseline and 4 weeks
|
Protein Levels and Activation Status of PDGFR in Prostate Cancer Tissue.
Délai: 4 years
|
We will perform immunohistochemistry staining on snap frozen specimens for endothelial and pericyte cell staining as previously described (42).
Frozen prostate tumor biopsies are sectioned at 6μm thickness and fixed with acetone for 10 minutes.
Endogenous peroxidase activity is quenched with 3% hydrogen peroxide for 15 min and then blocked with 5% normal serum.
The slides are incubated with the primary antibody (1;100) overnight at 4 C°, and washed with PBS.
Negative controls will be included by omission of the primary antibody.
Biotinylated donkey antimouse antibody (1:1000, v/v) will be applied for 30 min at room temperature, followed by application of ABC kit (Vector Lab, Inc., Burlingame, USA).
Slides are again washed in PBS and the color is developed by 5 min incubation with diaminobenzidine (DAB) solution.
Slides are then counterstained with hematoxylin.
Mean protein levels are presented.
|
4 years
|
Difference in Gene Expression Patterns Using Microarray Analysis
Délai: 4 years
|
Microarray data of 21 specimens from men enrolled who have undergone a prostatectomy and study treatment were compared to data from 21 prostatectomy only specimens.
We used previously developed genomic signatures to measure the deregulation of oncogenic pathways built using Bayesian Probit models for 'metagene' factors from a singular value decomposition of top differentially expressed genes.
A Monte Carlo Markov Chain was used to generate the predicted probabilities of pathway activity in normalized samples.
We predicted the activity of these pathways, leading to the generation of probability measures that have previously reflected the state of pathway activity.
These probability scores are interpreted as gene expression values to describe pathway activity patterns.
A probability near 0 indicates a low chance of pathway activity; a probability near 1 indicates a higher likelihood of activity.
Differences (treatment - control) in mean probability for each pathway are reported.
|
4 years
|
Interstitial Fluid Pressure (IFP)
Délai: 4 years
|
Measure Interstitial fluid pressure (IFP) pre-treatment and during treatment to indirectly measure the effect of Sunitinib malate on transcapillary transport and correlate with other biologic evidence of treatment effect.Eligible patients who sign consent will undergo a baseline transrectal ultrasound (TRUS)-guided measurement of tumor IFP.
Participants will then begin treatment with daily oral Sunitinib malate with biweekly monitoring for response and toxicity.
After 4 weeks of therapy, patients undergo a repeat TRUS and tumor IFP measurement.
Following a 1 to 2 week wash out period, patients undergo prostatectomy with pathologic tissue collection.
This will be performed as a means to evaluate whether Sunitinib malate has the ability to decrease tumor IFP, and whether this correlates with other tr
|
4 years
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Daniel J George, MD, Duke University
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 juillet 2006
Achèvement primaire (Réel)
1 septembre 2012
Achèvement de l'étude (Réel)
1 septembre 2013
Dates d'inscription aux études
Première soumission
4 mai 2008
Première soumission répondant aux critères de contrôle qualité
4 mai 2008
Première publication (Estimation)
6 mai 2008
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
4 août 2014
Dernière mise à jour soumise répondant aux critères de contrôle qualité
31 juillet 2014
Dernière vérification
1 mai 2014
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs
- Tumeurs urogénitales
- Tumeurs par site
- Tumeurs génitales, homme
- Maladies de la prostate
- Tumeurs prostatiques
- Effets physiologiques des médicaments
- Mécanismes moléculaires de l'action pharmacologique
- Inhibiteurs d'enzymes
- Agents antinéoplasiques
- Inhibiteurs de l'angiogenèse
- Agents modulateurs de l'angiogenèse
- Substances de croissance
- Inhibiteurs de croissance
- Inhibiteurs de protéine kinase
- Sunitinib
Autres numéros d'identification d'étude
- Pro00007396
- DUMC-8725 (Autre identifiant: Duke legacy protocol number)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Sunitinib Malate
-
Cogent Biosciences, Inc.RecrutementCancer métastatique | Tumeurs stromales gastro-intestinales avancéesÉtats-Unis, Corée, République de, Espagne, Royaume-Uni, Australie, France, Italie, Pays-Bas, Taïwan, Allemagne, Danemark, Hong Kong, Canada, Suède, Norvège, Mexique, Tchéquie, Argentine, Hongrie, Brésil, Chili, Pologne
-
AGO Study GroupPhilipps University Marburg Medical Center; HSK Reasearch GmbH WiesbadenComplétéCancer de l'ovaire épithélial réfractaire au platine | Cancer primitif du péritoine | Cancer de la trompe de FallopeAllemagne
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)Complété
-
PfizerComplétéTumeurs mammairesÉtats-Unis
-
California Pacific Medical Center Research InstitutePfizer; University of California, San FranciscoComplété
-
Asan Medical CenterComplétéCarcinome rénal métastatiqueCorée, République de
-
National Cancer Institute (NCI)ComplétéSyndromes myélodysplasiques | Leucémie myélomonocytaire chronique | Syndromes myélodysplasiques secondaires | Syndromes myélodysplasiques de novoCanada, États-Unis
-
National Cancer Institute (NCI)ComplétéMyélome multiple de stade I | Myélome multiple de stade II | Myélome multiple de stade III | Myélome multiple réfractaireÉtats-Unis
-
National Cancer Institute (NCI)Gynecologic Oncology GroupComplétéSarcome utérin récurrent | Léiomyosarcome utérinÉtats-Unis
-
Case Comprehensive Cancer CenterComplétéCarcinome rénal à cellules claires | Cancer des cellules rénales de stade IVÉtats-Unis